menu
    • menu

    Company profile for Amphista Therapeutics

    NEW Drugs in Dev: 1
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Amphista Therapeutics is an exciting spin out company founded by Advent Life Sciences and built on groundbreaking science from the laboratory of Professor Alessio Ciulli (University of Dundee), a world leader in the field of targeted protein degradation.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Amphista Therapeuticsunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    BioCity, Bo’Ness Rd, Newhouse, Chapelhall, Motherwell, ML1 5UH
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://amphista.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/amphista-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Amphista Therapeutics Unveils AMX-883's Potential In AML
    Amphista Therapeutics Unveils AMX-883's Potential In AML

    08 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/08/3201229/0/en/Amphista-Therapeutics-presents-new-preclinical-data-showing-the-potential-of-its-BRD9-Targeted-Glue-AMX-883-to-transform-the-treatment-paradigm-for-acute-myeloid-leukaemia.html

    GLOBENEWSWIRE
    08 Dec 2025
    Share Share
    Amphista Therapeutics Unveils AMX-883 Data At ASH Conference
    Amphista Therapeutics Unveils AMX-883 Data At ASH Conference

    25 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/25/3194189/0/en/Amphista-Therapeutics-announces-new-AMX-883-data-to-be-presented-at-the-ASH-Annual-Meeting-and-Exposition-and-provides-a-business-progress-update.html

    GLOBENEWSWIRE
    25 Nov 2025
    Share Share
    Amphista Therapeutics Showcases Targeted Glue Tech at Summit
    Amphista Therapeutics Showcases Targeted Glue Tech at Summit

    28 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/28/3175250/0/en/Amphista-Therapeutics-to-showcase-how-its-Targeted-Glue-technology-is-expanding-the-diversity-of-TPD-medicines-at-the-8th-Annual-TPD-Induced-Proximity-Summit-2025.html

    GLOBENEWSWIRE
    28 Oct 2025
    Share Share
    Amphista Shows BRD9 Degradation via DCAF16 in Nature Journal
    Amphista Shows BRD9 Degradation via DCAF16 in Nature Journal

    27 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/27/3174388/0/en/Amphista-Therapeutics-successful-degradation-of-a-key-cancer-target-BRD9-via-a-novel-mechanism-with-DCAF16-E3-ligase-published-in-Nature-Communications.html

    GLOBENEWSWIRE
    27 Oct 2025
    Share Share
    Amphista Appoints Leaders To Advance Glue Protein degraders
    Amphista Appoints Leaders To Advance Glue Protein degraders

    23 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/23/3171873/0/en/Amphista-Therapeutics-announces-three-key-strategic-leadership-appointments-to-drive-transition-of-its-Targeted-Glue-protein-degraders-into-clinical-development.html

    GLOBENEWSWIRE
    23 Oct 2025
    Share Share
    Amphista Therapeutics Nominates AMX-883, For Myeloid leukaemia
    Amphista Therapeutics Nominates AMX-883, For Myeloid leukaemia

    15 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/15/3166942/0/en/Amphista-Therapeutics-nominates-AMX-883-an-orally-available-Targeted-Glue-degrader-of-BRD9-as-its-first-clinical-development-candidate-for-the-treatment-of-acute-myeloid-leukaemia.html

    GLOBENEWSWIRE
    15 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search